The effect of specific brain phospholipid on the rat's allergic encephalomyelitis.
A new preparation which contains specific brain phospholipids (Gricertine) acts as a histamine liberator in CNS and protects rats from allergic encephalomyelitis. It is supposed that the protective effect of Gricertine on the allergic encephalomyelitis is based on its histamine-liberator properties which can occur during the first days of therapy: this would explain the large decrease of the brain histamine after 3 weeks of treatment. Gricertine is also able to remove clinical symptoms of allergic encephalomyelitis in rats. It is presumed that Gricertine may also be acting independently of that mechanism, in the way that it replaces phospholipids that disappeared in the cases where demyelinisation had taken place.
D000818:Animals; D001921:Brain / Q000378:metabolism; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D006636:Histamine Release / Q000187:drug effects; D009132:Muscles / Q000503:physiopathology; D010743:Phospholipids / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D013997:Time Factors
D010743:Phospholipids